BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38260237)

  • 1. Dose-Escalated Radiation Therapy as Primary Treatment for Residual Bladder Cancer After Transurethral Resection.
    Chang YC; Wu YY; Tsan DL; Yap WK; Fan KH; Chang JT; Shen EY
    Adv Radiat Oncol; 2024 Jan; 9(1):101302. PubMed ID: 38260237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
    Liao Z; Strom EA; Buzdar AU; Singletary SE; Hunt K; Allen PK; McNeese MD
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1191-200. PubMed ID: 10889372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes With Dose-Escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study.
    Murthy V; Masodkar R; Kalyani N; Mahantshetty U; Bakshi G; Prakash G; Joshi A; Prabhash K; Ghonge S; Shrivastava S
    Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):60-66. PubMed ID: 26547385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
    Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
    PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.
    Takaoka E; Matsui Y; Inoue T; Miyazaki J; Nakashima M; Kimura T; Oikawa T; Kawai K; Yoshimura K; Habuchi T; Ogawa O; Nishiyama H
    Jpn J Clin Oncol; 2013 Apr; 43(4):404-9. PubMed ID: 23444116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Taoka R; Matsuoka Y; Yamasaki M; Kani N; Honda T; Harada S; Tohi Y; Kato T; Okazoe H; Tsunemori H; Ueda N; Sugimoto M
    Photodiagnosis Photodyn Ther; 2022 Jun; 38():102838. PubMed ID: 35381368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Outcomes With Dose Escalation Using Modern Radiotherapy Techniques: A Retrospective Review of Anal Cancer Treated at a Large Academic Institution Between 2010 and 2016.
    Murchison SC; DeVries KJ; Atrchian S
    Cureus; 2020 Oct; 12(10):e10989. PubMed ID: 33209545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.
    Untiedt S; Rolf D; Scobioala S; Wolters H; Elsayad K; Oertel M; Kittel C; Pascher A; Rijcken E; Ullerich H; Glasbrenner B; Eich HT
    Strahlenther Onkol; 2023 Aug; 199(8):749-760. PubMed ID: 36862155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
    Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive Radiotherapy for Carcinoma of the Urinary Bladder: Long-term Outcomes With Dose Escalation.
    Murthy V; Gupta P; Baruah K; Krishnatry R; Joshi A; Prabhash K; Noronha V; Menon S; Pal M; Prakash G; Bakshi G
    Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):646-652. PubMed ID: 31301959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
    Heer R; Lewis R; Duncan A; Penegar S; Vadiveloo T; Clark E; Yu G; Mariappan P; Cresswell J; McGrath J; N'Dow J; Nabi G; Mostafid H; Kelly J; Ramsay C; Lazarowicz H; Allan A; Breckons M; Campbell K; Campbell L; Feber A; McDonald A; Norrie J; Orozco-Leal G; Rice S; Tandogdu Z; Taylor E; Wilson L; Vale L; MacLennan G; Hall E
    Health Technol Assess; 2022 Oct; 26(40):1-144. PubMed ID: 36300825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
    Dearnaley DP; Hall E; Lawrence D; Huddart RA; Eeles R; Nutting CM; Gadd J; Warrington A; Bidmead M; Horwich A
    Br J Cancer; 2005 Feb; 92(3):488-98. PubMed ID: 15685244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.
    Kikuchi H; Abe T; Matsumoto R; Osawa T; Maruyama S; Murai S; Shinohara N
    Int J Urol; 2022 Mar; 29(3):251-258. PubMed ID: 34894009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy.
    Skinner HD; Strom EA; Motwani SB; Woodward WA; Green MC; Babiera G; Booser DJ; Meric-Bernstam F; Buchholz TA
    Radiat Oncol; 2013 Jan; 8():13. PubMed ID: 23311297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
    Caffo O; Fellin G; Graffer U; Valduga F; Bolner A; Luciani L; Tomio L; Galligioni E
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1310-6. PubMed ID: 14630267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
    Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
    J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending?
    Jen YM; Lin YS; Su WF; Hsu WL; Hwang JM; Chao HL; Liu DW; Chen CM; Lin HY; Wu CJ; Chang LP; Shueng PW
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):14-22. PubMed ID: 12182970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
    Gamal El-Deen HS
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.